Table 3.

Secondary clinical outcomes.

2 weeks, duration of symptoms	RV-A	RV-C	non-RV	p-value
Cough, days	10 (5, 12)	8 (5, 11)	5 (4, 7)	0.15
Expiratory breathing difficulty, days	2 (1, 6)	2 (0, 5)	2 (0, 4)	0.58
Noisy breathing, days	7 (3, 9)	6 (3, 9)	5 (2, 9)	0.90
Rhinitis, days	9 (4, 11)	8 (4, 10)	6 (4, 10)	0.50
Nocturnal symptoms, days	1 (0, 4)	1 (0, 4)	2 (0, 3)	0.89
Use of bronchodilator, days	7 (1, 11)	5 (2, 7)	3 (0, 7)	0.28
2 months, recurrent wheezing
Doctor visit, %*	24%	56%	12%	0.001
Hospitalization, %*	0%	16%	4.2%	0.14
Oral corticosteroid, %*	24%	47%	4.2%	0.001
Inhaled corticosteroid, %*	5.9%	11%	4.0%	0.68

Values are shown as medians (interquartile range) and OR (95% CI). Data were analyzed by Kruskall-Wallis test for 2 weeks secondary outcomes and by Pearson’s chi-square test for 2 months secondary outcome.

^*For expiratory breathing difficulty. Statistically significant results are marked with bold.